Castration-resistant prostate cancer (mCRPC)
JANXJanux TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for JANX007 (PSMA-TRACTr) in Castration-resistant prostate cancer (mCRPC). The expected timing is based on the latest available company guidance and may change.
7/17/23- Presented interim clinical data. 5/7/24- Ongoing enrollment. 2/3/24- Ph1a data reported. 5/5/25- Ph1b initiated. 12/1/25- Updated interim data reported. 02/26/26:- Ongoing Ph1b enrollment and expansion cohorts; additional JANX007 clinical data expected in 2026. 04/16/26:- Early clinical data highlighted; no new timelines for additional data readout. 05/07/26:- Ph1b enrollment and darolutamide combo cohorts ongoing; additional clinical data at medical congress expected in H1 2027. 08/06/26:- Ph1b enrollment continues; additional clinical data expected at medical congress in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.